Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Erfonrilimab, an antibody targeting PD-L1 × CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Divozilimab, an antibody targeting CD20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dafsolimab, an antibody targeting CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bentracimab, an antibody targeting AR-C124910XX.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Amlitelimab, an antibody targeting OX40L.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Acasunlimab, an antibody targeting PD-L1 × 4-1BB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zamerovimab, an antibody targeting Rabies Virus Spike Glycoprotein G.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Semzuvolimab, an antibody targeting CD4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rocatinlimab, an antibody targeting OX40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pulocimab, an antibody targeting VEGFR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Paridiprubart, an antibody targeting TLR4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nofazinlimab, an antibody targeting PD-1.